SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (271)5/26/1998 11:43:00 PM
From: Spekulatius  Read Replies (1) of 410
 
I have held Genz for a couple of month 18 month ago and studied it in detail. I like there approach to niche solutions with less competition like the Ceredase but what I don't like is that they issue a lot of shares. The No.of shares has grown somewhat like 80% since 92,while the revenue has less than tripled.If we look at the rev. for 1 share it basically has moved from 4$ in 92 to a bit less than 8$ in 98. Well that's solid but not outstanding. Still the earnings a driven by Ceredase and they need to develop a second Cash Cow to sustain growth. I don't see anything coming for the next two years. Thus I think,this is more a value investment which may yield decent returns with less risk than other Biotechs but also less potential for outstanding returns.
These are the reasons why the share price is comparatively low
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News